Selumetinib
Borderline Epithelial Tumor Of Ovary
National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Borderline Epithelial Tumor Of Ovary cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capecitabine National Cancer Institute (NCI) | Phase 3 | B |
OXALIPLATIN National Cancer Institute (NCI) | Phase 3 | B |
Carboplatin National Cancer Institute (NCI) | Phase 3 | B |
Belinostat National Cancer Institute (NCI) | Phase 2 | B |
Irinotecan National Cancer Institute (NCI) | Phase 1 | CC |
Valproic Acid Barbara Ann Karmanos Cancer Institute | Phase 1 | CC |
DEXAMETHASONE Barbara Ann Karmanos Cancer Institute | Phase 1 | CC |
7-hydroxystaurosporine National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Selumetinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →